LOGIN  |  REGISTER
Chimerix
Astria Therapeutics

P3 Health Partners to Present at the BTIG Digital Health Forum

November 16, 2023 | Last Trade: US$9.24 0.58 -5.91

HENDERSON, Nev. / Nov 16, 2023 / Business Wire / P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that leadership will participate in the BTIG Digital Health Forum, being held virtually, on Monday, November 20, 2023, including a panel discussion with Dr. Sherif Abdou, Chief Executive Officer and Co-founder of P3, at 12:00 p.m. PT/3:00 p.m. ET.

About P3 Health Partners (NASDAQ: PIII)

P3 Health Partners Inc. is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 2,700 affiliated primary care providers across the country. Our local teams of health care professionals manage the care of thousands of patients in 18 counties across five states. P3 supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the P3 care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. For more information, visit www.p3hp.org and follow us on LinkedIn and Facebook.com/p3healthpartners.

Chimerix

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page